Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...

Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed ...

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes ...

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- ...

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses feedback he’s received from colleagues at Case ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.